The update reports new product approvals and collaborations in therapeutic delivery technologies, indicating a growth trend in the industry.
November 2025 saw the approval of a number of products which employ a variety of delivery technologies including Johnson and Johnson's DARZALEX FASPRO (with Haloyzyme's ENHAZE), Merck's KEYTRUDA QLEX, and Regeneron's EYLEA HD. It was also a busy month for acquisitions with Halozyme completing the acquisition of Elektrofi which gives it access to the microparticulate technology Hypercon. Halozyme also announced a collaboration with the Dutch company Merus, for the development of a subcutaneous formulation of petosemtamab. Positive clinical trial data was announced for a number of companies including EyePoint, Tiziana, Nasus, and Tonix.
No takes yet. Share an insight, caveat, or question.
Elaine Harris (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: